OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B
Miles Wang, an OpenAI researcher, is leaving the company to start a new AI-driven drug discovery startup. He is reportedly in talks to raise roughly $200 million at a $2 billion valuation, with Lightspeed potentially leading the round. The venture aims to develop models that can repurpose existing drugs and revive candidates that failed in earlier trials.
- ▪Wang’s departure from OpenAI follows his work on AI methods to accelerate scientific discovery.
- ▪Funding discussions suggest investor interest, though Wang has disputed the reported valuation and amount.
- ▪Lightspeed is in talks to lead a potential $200 million financing round for the startup.
- ▪The new company may focus on AI models that identify new uses for FDA‑approved drugs and previously failed compounds.
TechCrunch files mainly under tech. We currently carry 596 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | TechCrunch |
| Canonical URL | https://techcrunch.com/2026/07/14/openai-researcher-miles-wang-in-talks-to-launch-ai-drug-discovery-startup-valued-at-2b/ |
| Publication time | Wed, 15 Jul 2026 00:27:04 +0000 |
| Retrieval time | 2026-07-15T01:04:52.552Z |
| Last seen | 2026-07-15T01:04:52.552Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | EaQ2yW_ayNVM |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company. Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change. Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at TechCrunch.
Discussion
0 commentsMore from TechCrunch
